Rheumatoid Arthritis
11
Companies
17
Drug Programs
5
Phase 3
0
Upcoming PDUFAs
Coherus Oncology, Inc.
Etanercept
Eli Lilly and Company
cDMARD
Gilead Sciences, Inc.
MTX
Amgen Inc.
Etanercept Liquid
Sanofi
Sulfasalazine
Ionis Pharmaceuticals, Inc.
ISIS 104838
Aclaris Therapeutics, Inc.
ATI-450
AnaptysBio, Inc.
Rosnilimab
Galapagos NV
GLPG0259 oral capsule
Galapagos NV
GLPG0634
Ionis Pharmaceuticals, Inc.
ISIS CRP Rx or Placebo
Galapagos NV
Placebo
Galapagos NV
GLPG3970
Vertex Pharmaceuticals Incorporated
VX-702
Vertex Pharmaceuticals Incorporated
VX-509
Aclaris Therapeutics, Inc.
ATI-450 50 mg oral tablet BID
XBiotech Inc.
Natrunix
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CHRS Coherus Oncology, Inc. | Etanercept | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | cDMARD | Phase 3 | — | — | — |
| GILD Gilead Sciences, Inc. | MTX | Phase 3 | — | — | — |
| AMGN Amgen Inc. | Etanercept Liquid | Phase 3 | — | — | — |
| SNY Sanofi | Sulfasalazine | Phase 3 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS 104838 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 | Phase 2 | — | — | — |
| ANAB AnaptysBio, Inc. | Rosnilimab | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0259 oral capsule | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0634 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS CRP Rx or Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG3970 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-702 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-509 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 50 mg oral tablet BID | Phase 2 | — | — | — |
| XBIT XBiotech Inc. | Natrunix | Phase 2 | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.